On July 30, 2022 EpiAxis Therapeutics reported to update venture capitalists, corporate investors, private investors and investment bankers on its latest epigenetic findings (Press release, EpiAxis Therapeutics, JUL 30, 2022, View Source;utm_medium=rss&utm_campaign=epiaxis-highlights-july-2022 [SID1234617155]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company is currently working with The Sage Group to raise US$12million to advance a candidate into an IND enabled program following the findings of its pioneering clinical trial EPI-PRIMED. This was the first time that an epigenetic inhibitor had been used in combination with chemotherapy to treat metastatic breast cancer and the findings give EpiAxis a solid foundation for its next clinical trial using its novel peptide inhibitors..
EpiAxis CEO Dr Jeremy Chrisp pitched at youngStartup Ventures Network’s Venture Summit West 2022, which was held in Silicon Valley from 19-20 July 2022.
The exclusive venture summit focused on emerging and early stage companies as well as showcasing more than 100 top innovators in the tech, fintech, cleantech, lifesciences, healthcare and medtech sectors.
Venture Summit West only accepts presenters who meet strict criteria based on industry, stage, business model, size of the target audience, milestones achieved to date, and whether the company would be of interest to the featured investors. Its presentation programs are geared toward emerging growth companies looking to gain visibility among active investors and raise capital.
"We were excited to be one of only 200 companies worldwide to earn a coveted presentation spot at the 10th annual Venture Summit West," said Dr Chrisp. "It was energising to increase investor awareness in the advances that have been made in epigenetic treatments for metastatic cancer."
Wholesale Investor also shared the results of EpiAxis’ EPI-PRIMED trial with its engaged and growing ecosystem of over 29,300 high-net-worth investors, fund managers, family offices, PE and VC firms, government bodies and industry participants.
Wholesale Investor is Australasia’s leading investment platform. It connects innovative, emerging companies that are looking to raise capital with its active investor base.